Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ESTEE LAUDER COMPANIES INCEL · Entity 3097 | Director | September 15, 2021 | September 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ESTEE LAUDER COMPANIES INC
Report date September 15, 2021 · Filed September 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Units (Share Payout)SEC Table II · derivative / convertible security | Direct | 22,892.11 |
Reported balance
After 2021-09-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-09-15 · Grant · Acquired 37.12 · Balance 22,892.11 F1: Not applicable. F2: Represents reinvestment of dividend equivalents on outstanding stock units. F3: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. |
| Stock Units (Cash Payout)SEC Table II · derivative / convertible security | Direct | 80,015.93 |
Reported balance
After 2021-09-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-09-15 · Grant · Acquired 129.78 · Balance 80,015.93 F1: Not applicable. F2: Represents reinvestment of dividend equivalents on outstanding stock units. F3: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. |
Filing footnotes · ownership attribution and instrument terms
F1: Not applicable.
F2: Represents reinvestment of dividend equivalents on outstanding stock units.
F3: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARATANA THERAPEUTICS, INC.
Report date July 18, 2019 · Filed July 18, 2019
Section 16 reporting ended · disclosed 2019-07-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 1
1 source rowRow 1 · 2019-07-18 · Disposition to issuer · Disposed 82,985 · Balance 0 F1: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2) F2: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.18 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-07-18 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.27 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-07-18 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.12 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-07-18 · Disposition to issuer · Disposed 7,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.84 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-07-18 · Disposition to issuer · Disposed 7,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-07-18 · Disposition to issuer · Disposed 7,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-07-18 · Disposition to issuer · Disposed 7,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2)
F2: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration").
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards.
F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2021 Filed Sep 16, 2021 15:52 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Cash Payout) · Derivative | 129.78 | $326.25 | $42,340.73 |
DisclosureSEC source: 0001001250-21-000163 · wf-form4_163180754255819.xml · derivative · entry 2 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,015.93 Underlying: Class A Common Stock · 129.78 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 15:52 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Share Payout) · Derivative | 37.12 | $326.25 | $12,110.40 |
DisclosureSEC source: 0001001250-21-000163 · wf-form4_163180754255819.xml · derivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,892.11 Underlying: Class A Common Stock · 37.12 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 20:34 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Cash Payout) · Derivative | 119.29 | $320.63 | $38,247.95 |
DisclosureSEC source: 0001001250-21-000105 · edgar.xml · derivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,886.15 Underlying: Class A Common Stock · 119.29 shares Expires not disclosed F1 · derivative.exercise_price: Each Stock Unit (cash payout) is convertible into cash equal to the value of one share of Class A Common Stock (i.e. 1:1). F2 · kind: Represents grant of Stock Units in lieu of cash for quarterly presiding director, board, committee chair, and committee member retainers. F3 · derivative.exercise_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. F3 · derivative.expiration_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 20:10 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Cash Payout) · Derivative | 139.37 | $302.81 | $42,202.63 |
DisclosureSEC source: 0001001250-21-000095 · edgar.xml · derivative · entry 2 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,766.86 Underlying: Class A Common Stock · 139.37 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 20:10 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Share Payout) · Derivative | 39.93 | $302.81 | $12,091.20 |
DisclosureSEC source: 0001001250-21-000095 · edgar.xml · derivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,854.99 Underlying: Class A Common Stock · 39.93 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 15:32 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | SaleClass A Common Stock | 2,740 | $302.23 | $828,110.20 |
DisclosureSEC source: 0001001250-21-000086 · edgar.xml · nonDerivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F2 · price: Sales prices range from $301.84 to $302.59, inclusive. Read SEC document |
| May 18, 2021 Filed May 19, 2021 18:05 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Cash Payout) · Derivative | 129.13 | $296.20 | $38,248.31 |
DisclosureSEC source: 0001001250-21-000078 · edgar.xml · derivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,627.49 Underlying: Class A Common Stock · 129.13 shares Expires not disclosed F1 · derivative.exercise_price: Each Stock Unit (cash payout) is convertible into cash equal to the value of one share of Class A Common Stock (i.e. 1:1). F2 · kind: Represents grant of Stock Units in lieu of cash for quarterly presiding director, board, committee chair, and committee member retainers. F3 · derivative.exercise_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. F3 · derivative.expiration_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:23 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Cash Payout) · Derivative | 145.25 | $289.55 | $42,057.14 |
DisclosureSEC source: 0001001250-21-000046 · edgar.xml · derivative · entry 2 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,498.36 Underlying: Class A Common Stock · 145.25 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:23 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Share Payout) · Derivative | 41.68 | $289.55 | $12,068.44 |
DisclosureSEC source: 0001001250-21-000046 · edgar.xml · derivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,815.06 Underlying: Class A Common Stock · 41.68 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 20:46 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Cash Payout) · Derivative | 132.1 | $289.54 | $38,248.23 |
DisclosureSEC source: 0001001250-21-000032 · edgar.xml · derivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,353.11 Underlying: Class A Common Stock · 132.1 shares Expires not disclosed F1 · derivative.exercise_price: Each Stock Unit (cash payout) is convertible into cash equal to the value of one share of Class A Common Stock (i.e. 1:1). F2 · kind: Represents grant of Stock Units in lieu of cash for quarterly presiding director, board, committee chair, and committee member retainers. F3 · derivative.exercise_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. F3 · derivative.expiration_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. Read SEC document |
| February 24, 2021 Filed Feb 24, 2021 22:15 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | SaleClass A Common Stock | 3,000 | $295.55 | $886,650.00 |
DisclosureSEC source: 0001001250-21-000022 · edgar.xml · nonDerivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,740 F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F2 · price: Sales prices range from $295.22 to $295.80, inclusive. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:12 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Cash Payout) · Derivative | 167.33 | $250.40 | $41,899.43 |
DisclosureSEC source: 0001001250-20-000157 · edgar.xml · derivative · entry 2 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,221.01 Underlying: Class A Common Stock · 167.33 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:12 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Share Payout) · Derivative | 48.1 | $250.40 | $12,044.24 |
DisclosureSEC source: 0001001250-20-000157 · edgar.xml · derivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,773.38 Underlying: Class A Common Stock · 48.1 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| November 18, 2020 Filed Nov 18, 2020 21:14 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | Exercise / conversionOption (Right to Buy) · Derivative | 1,905 | Not disclosed Strike: $190.99 | Not disclosed |
DisclosureSEC source: 0001001250-20-000147 · edgar.xml · derivative · entry 5 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 1,905 shares Expires 2029-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Stock Options granted pursuant to the Issuer's Non-Employee Director Share Incentive Plan. F2 · price: Not applicable. Read SEC document |
| November 18, 2020 Filed Nov 18, 2020 21:14 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | Exercise / conversionOption (Right to Buy) · Derivative | 2,329 | Not disclosed Strike: $143.39 | Not disclosed |
DisclosureSEC source: 0001001250-20-000147 · edgar.xml · derivative · entry 4 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 2,329 shares Expires 2028-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Stock Options granted pursuant to the Issuer's Non-Employee Director Share Incentive Plan. F2 · price: Not applicable. Read SEC document |
| November 18, 2020 Filed Nov 18, 2020 21:14 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | SaleClass A Common Stock | 4,234 | $255.08 | $1,080,008.72 |
DisclosureSEC source: 0001001250-20-000147 · edgar.xml · nonDerivative · entry 3 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,740 Read SEC document |
| November 18, 2020 Filed Nov 18, 2020 21:14 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | Exercise / conversionClass A Common Stock | 1,905 | $190.99 | $363,835.95 |
DisclosureSEC source: 0001001250-20-000147 · edgar.xml · nonDerivative · entry 2 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2020 Filed Nov 18, 2020 21:14 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | Exercise / conversionClass A Common Stock | 2,329 | $143.39 | $333,955.31 |
DisclosureSEC source: 0001001250-20-000147 · edgar.xml · nonDerivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 15:12 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Share Payout) · Derivative | 328.57 | $0.00 | $0.00 |
DisclosureSEC source: 0001001250-20-000133 · edgar.xml · derivative · entry 2 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,725.28 Underlying: Class A Common Stock · 328.57 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Amended and Restated Non-Employee Director Share Incentive Plan. F2 · derivative.exercise_price: Each stock unit (share payout) is convertible into one share of Class A Common Stock (i.e. 1:1). F3 · derivative.exercise_date: The stock units (share payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. F3 · derivative.expiration_date: The stock units (share payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 15:12 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantOption (Right to Buy) · Derivative | 1,516 | $0.00 Strike: $247.35 | $0.00 |
DisclosureSEC source: 0001001250-20-000133 · edgar.xml · derivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,516 Underlying: Class A Common Stock · 1,516 shares Expires 2030-11-10 F1 · security: Granted pursuant to the Issuer's Amended and Restated Non-Employee Director Share Incentive Plan. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 19:14 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Cash Payout) · Derivative | 173.87 | $217.76 | $37,861.93 |
DisclosureSEC source: 0001001250-20-000094 · edgar.xml · derivative · entry 2 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,053.69 Underlying: Class A Common Stock · 173.87 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 19:14 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Share Payout) · Derivative | 49.25 | $217.76 | $10,724.68 |
DisclosureSEC source: 0001001250-20-000094 · edgar.xml · derivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,396.71 Underlying: Class A Common Stock · 49.25 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 15:17 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | SaleClass A Common Stock | 2,000 | $200.64 | $401,280.00 |
DisclosureSEC source: 0001001250-20-000047 · edgar.xml · nonDerivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,740 F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F2 · price: Sales prices range from $200.61 to $200.66, inclusive. Read SEC document |
| March 16, 2020 Filed Mar 17, 2020 15:42 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Cash Payout) · Derivative | 253.33 | $148.98 | $37,741.10 |
DisclosureSEC source: 0001001250-20-000022 · edgar.xml · derivative · entry 2 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,879.81 Underlying: Class A Common Stock · 253.33 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| March 16, 2020 Filed Mar 17, 2020 15:42 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Share Payout) · Derivative | 71.77 | $148.98 | $10,692.29 |
DisclosureSEC source: 0001001250-20-000022 · edgar.xml · derivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,347.46 Underlying: Class A Common Stock · 71.77 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 20:07 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | SaleClass A Common Stock | 600 | $193.39 | $116,034.00 |
DisclosureSEC source: 0001001250-20-000017 · edgar.xml · nonDerivative · entry 2 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,740 F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $193.26 to $193.54, inclusive. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 20:07 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | SaleClass A Common Stock | 3,400 | $192.69 | $655,146.00 |
DisclosureSEC source: 0001001250-20-000017 · edgar.xml · nonDerivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,340 F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F2 · price: Sales prices range from $192.27 to $193.25, inclusive. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 20:45 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Cash Payout) · Derivative | 182.77 | $209.27 | $38,248.28 |
DisclosureSEC source: 0001001250-20-000014 · edgar.xml · derivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,626.49 Underlying: Class A Common Stock · 182.77 shares Expires not disclosed F1 · derivative.exercise_price: Each Stock Unit (cash payout) is convertible into cash equal to the value of one share of Class A Common Stock (i.e. 1:1). F2 · kind: Represents grant of Stock Units in lieu of cash for quarterly presiding director, board, committee chair, and committee member retainers. F3 · derivative.exercise_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. F3 · derivative.expiration_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. Read SEC document |
| December 16, 2019 Filed Dec 17, 2019 19:22 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Cash Payout) · Derivative | 184.11 | $204.03 | $37,563.96 |
DisclosureSEC source: 0001001250-19-000146 · edgar.xml · derivative · entry 2 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,443.72 Underlying: Class A Common Stock · 184.11 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| December 16, 2019 Filed Dec 17, 2019 19:22 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Share Payout) · Derivative | 52.28 | $204.03 | $10,666.69 |
DisclosureSEC source: 0001001250-19-000146 · edgar.xml · derivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,275.69 Underlying: Class A Common Stock · 52.28 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 21:14 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Cash Payout) · Derivative | 200.27 | $190.99 | $38,249.57 |
DisclosureSEC source: 0001001250-19-000133 · edgar.xml · derivative · entry 3 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,259.6 Underlying: Class A Common Stock · 200.27 shares Expires not disclosed F4 · security: Reflects grant of stock units in lieu of cash for quarterly board, committee, committee chair, and presiding director retainers. F5 · derivative.exercise_price: Each stock unit (cash payout) is convertible into cash equal to the value of one share of Class A Common Stock (i.e. 1:1). F6 · derivative.exercise_date: The stock units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. F6 · derivative.expiration_date: The stock units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 21:14 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Share Payout) · Derivative | 400.77 | $0.00 | $0.00 |
DisclosureSEC source: 0001001250-19-000133 · edgar.xml · derivative · entry 2 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,223.41 Underlying: Class A Common Stock · 400.77 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Amended and Restated Non-Employee Director Share Incentive Plan. F2 · derivative.exercise_price: Each stock unit (share payout) is convertible into one share of Class A Common Stock (i.e. 1:1). F3 · derivative.exercise_date: The stock units (share payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. F3 · derivative.expiration_date: The stock units (share payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 21:14 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantOption (Right to Buy) · Derivative | 1,905 | $0.00 Strike: $190.99 | $0.00 |
DisclosureSEC source: 0001001250-19-000133 · edgar.xml · derivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,905 Underlying: Class A Common Stock · 1,905 shares Expires 2029-11-15 F1 · security: Granted pursuant to the Issuer's Amended and Restated Non-Employee Director Share Incentive Plan. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 16:44 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Cash Payout) · Derivative | 173.93 | $192.55 | $33,490.22 |
DisclosureSEC source: 0001001250-19-000104 · edgar.xml · derivative · entry 2 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,059.33 Underlying: Class A Common Stock · 173.93 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 16:44 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Share Payout) · Derivative | 48.62 | $192.55 | $9,361.78 |
DisclosureSEC source: 0001001250-19-000104 · edgar.xml · derivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,822.64 Underlying: Class A Common Stock · 48.62 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 19:46 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001209191-19-042720 · doc4.xml · derivative · entry 7 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 19:46 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $4.36 | Not disclosed |
DisclosureSEC source: 0001209191-19-042720 · doc4.xml · derivative · entry 6 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 19:46 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $6.84 | Not disclosed |
DisclosureSEC source: 0001209191-19-042720 · doc4.xml · derivative · entry 5 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 19:46 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $6.12 | Not disclosed |
DisclosureSEC source: 0001209191-19-042720 · doc4.xml · derivative · entry 4 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 19:46 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $14.27 | Not disclosed |
DisclosureSEC source: 0001209191-19-042720 · doc4.xml · derivative · entry 3 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 19:46 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $11.18 | Not disclosed |
DisclosureSEC source: 0001209191-19-042720 · doc4.xml · derivative · entry 2 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 19:46 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerCommon Stock | 82,985 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-042720 · doc4.xml · nonDerivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2) F2 · shares: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration"). F3 · shares: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards. F1 · price: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2) F2 · price: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration"). Read SEC document |
| July 11, 2019 Filed Jul 12, 2019 18:15 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Cash Payout) · Derivative | 205.55 | $186.08 | $38,248.74 |
DisclosureSEC source: 0001001250-19-000070 · edgar.xml · derivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,885.4 Underlying: Class A Common Stock · 205.55 shares Expires not disclosed F1 · derivative.exercise_price: Each Stock Unit (cash payout) is convertible into cash equal to the value of one share of Class A Common Stock (i.e. 1:1). F2 · kind: Represents grant of Stock Units in lieu of cash for quarterly presiding director, board, committee chair, and committee member retainers. F3 · derivative.exercise_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. F3 · derivative.expiration_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 19:35 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Cash Payout) · Derivative | 187.6 | $177.62 | $33,321.51 |
DisclosureSEC source: 0001001250-19-000062 · edgar.xml · derivative · entry 2 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,679.85 Underlying: Class A Common Stock · 187.6 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 19:35 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Share Payout) · Derivative | 52.58 | $177.62 | $9,339.26 |
DisclosureSEC source: 0001001250-19-000062 · edgar.xml · derivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,774.02 Underlying: Class A Common Stock · 52.58 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units. F3 · derivative.exercise_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. F3 · derivative.expiration_date: The stock units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 17:53 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-19-035633 · doc4.xml · derivative · entry 2 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-05 F1 · derivative.exercise_date: Vests on the earlier of (i) the first anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to continued service as a member of the Board of Directors of the Issuer through such vesting date. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 17:53 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035633 · doc4.xml · nonDerivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,985 Read SEC document |
| May 21, 2019 Filed May 22, 2019 21:21 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GiftClass A Common Stock | 1,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001001250-19-000056 · edgar.xml · nonDerivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,740 F1 · price: Not applicable. Read SEC document |
| May 17, 2019 Filed May 20, 2019 19:01 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | GrantStock Units (Cash Payout) · Derivative | 228.19 | $167.62 | $38,249.21 |
DisclosureSEC source: 0001001250-19-000053 · edgar.xml · derivative · entry 1 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,492.25 Underlying: Class A Common Stock · 228.19 shares Expires not disclosed F1 · derivative.exercise_price: Each Stock Unit (cash payout) is convertible into cash equal to the value of one share of Class A Common Stock (i.e. 1:1). F2 · kind: Represents grant of Stock Units in lieu of cash for quarterly presiding director, board, committee chair, and committee member retainers. F3 · derivative.exercise_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. F3 · derivative.expiration_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company. Read SEC document |
| May 03, 2019 Filed May 3, 2019 20:52 UTC | ESTEE LAUDER COMPANIES INC EL · Entity 3097 | Exercise / conversionOption (Right to Buy) · Derivative | 4,374 | Not disclosed Strike: $71.33 | Not disclosed |
DisclosureSEC source: 0001001250-19-000042 · edgar.xml · derivative · entry 14 Hockaday Irvine O Jr · CIK 0001113487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 4,374 shares Expires 2024-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Stock Options granted pursuant to the Issuer's Non-Employee Director Share Incentive Plan. F6 · price: Not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.